Niacin: the evidence, clinical use, and future directions. (Q34228636)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

title

Niacin: the evidence, clinical use, and future directions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Andrew S Kim

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

Rosco S Gore

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

Allen J Taylor

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

Current Atherosclerosis Reports

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

49-59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Athero

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Nicotinic acid: pharmacological effects and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Safety of extended-release niacin/laropiprant in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Genetic variants associated with Lp(a) lipoprotein level and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

"Flush-free niacin": dietary supplement may be "benefit-free".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Flushing and the HDL-C response to extended-release niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Effects of niacin on glucose control in patients with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

The safety of niacin in the US Food and Drug Administration adverse event reporting database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Novel patent publications on high-affinity nicotinic acid receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11883-011-0212-1

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2

21 January 2018

1 reference

12 December 2020

Future of GPR109A agonists in the treatment of dyslipidaemia

1 reference

12 December 2020

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study p

1 reference

12 December 2020

Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups

1 reference

12 December 2020

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

1 reference

12 December 2020

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

The effect of aspirin on niacin-induced cutaneous reactions

1 reference

12 December 2020

Aspirin blocks nicotinic acid-induced flushing

1 reference

12 December 2020

Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial

1 reference

12 December 2020

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3

1 reference

12 December 2020

10.1007/S11883-011-0212-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037771 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

15 January 2020

1049237920

0 references

Fatcat ID

release_2tr6msahpvh6dozxacucualld4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2tr6msahpvh6dozxacucualld4

24 November 2022

mapped directly with Wikidata item

1 reference